Cystic Fibrosis Foundation

Rule Changes

As of May 2026: Celebrated generic availability while crediting Vertex research

A generic version of Trikafta—the cystic fibrosis drug that extends lives by decades—hit the market at $12,750 per year. That's 95% cheaper than Vertex Pharmaceuticals' brand-name version, which costs over $300,000 annually. The brand-name drug has generated billions while remaining out of reach for patients in developing nations and many Americans with inadequate insurance.

Updated May 20